(redirected from Cyanokit)


an analogue of cyanocobalamin (vitamin B12) having exceptionally long-acting hematopoietic activity; used in the treatment of pernicious anemia and other macrocytic anemias.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.


Vitamin B12b, differing from cyanocobalamin (vitamin B12) in the presence of a hydroxyl ion in place of the cyanide ion at the sixth coordinate position on the cobalt atom.
See also: vitamin B12.
Synonym(s): hydroxocobemine
Farlex Partner Medical Dictionary © Farlex 2012


A chemical compound, also called vitamin B12a, which is the immediate precursor to cyanocobalamin (vitamin B12) in the body and that has also been investigated as an antidote in cyanide poisoning, although it is not currently approved for such use in the U.S.
See also: amyl nitrite, sodium nitrite, sodium thiosulfate
Synonym(s): hydroxocobalamin.
Medical Dictionary for the Health Professions and Nursing © Farlex 2012


Vitamin B12. This is the specific treatment for PERNICIOUS ANAEMIA and is highly effective unless neurological damage has already occurred. The drug is on the WHO official list. Brand names are Cobalin-H and Neo-Cytamen.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
Initial reports suggested Cyanokit administration was safe prior to organ transplantation [18].
Manufacturer Celotex stated that the insulation would have released 'toxic gases' if it caught fire.King's College Hospital confirmed that three of its 12 Grenfell patients were treated with the hydrogen cyanide antidote Cyanokit. The renovation works were inspected 16 times by Kensington and Chelsea council, it has been reported.
Due to the favorable safety and efficacy profile, hydroxocobalamin has been proposed as an antidote for cyanide poisoning and Cyanokit (hydroxocobalamin) was approved by FDA in 2006 [12].
[12] Cyanokit (hydroxocobalamin for injection) product information.
M2 PHARMA-April 29, 2011-Merck Serono gets FDA nod for new presentation of Cyanokit 5 g(C)2011 M2 COMMUNICATIONS
29 April 2011 - Switzerland-based Merck Serono, a division of Merck KGaA, announced today that a new presentation of Cyanokit 5 g (hydroxocobalamin) has been approved by the US Food and Drug Administration (FDA).
NORDIC BUSINESS REPORT-1 April 2010-Swedish Orphan Biovitrum to expand Cyanokit distribution(C)1994-2010 M2 COMMUNICATIONS http://www.m2.com
M2 EQUITYBITES-1 April 2010-Swedish Orphan Biovitrum to expand Cyanokit distribution(C)2010 M2 COMMUNICATIONS http://www.m2.com